ScreenerHero

FDMT4D Molecular Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · 4dmoleculartherapeutics.com
15.83USD-5.55%Mkt Cap: 874.52M $P/E: —

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap874.52M $
Enterprise Value567.31M $
Revenue (TTM)92.01M $
Gross Profit-145.10M $
Net Income (TTM)-140.11M $
Revenue/Share1.424 USD
Last Price15.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees196
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.94
PEG—
EV/EBITDA-3.00
EV/Revenue6.17
P/S9.67
P/B2.18
EPS (TTM)-2.52
EPS (Forward)-4.09
52W Range
5.97090% of range16.91
52W High16.91 USD
52W Low5.970 USD
Profitability
Gross Margin-157.70%
Oper. Margin-2037.16%
EBITDA Margin-205.30%
Profit Margin-164.43%
ROE-27.71%
ROA-24.72%
Growth
Revenue Growth25106.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-109.08M $
CapEx (TTM)536.00K $
FCF Margin-98.66%
FCF Yield-10.38%
Net Debt-322.12M $
Net Debt/EBITDA1.71
Balance Sheet
Debt/Equity0.04
Current Ratio8.03
Quick Ratio7.68
Book Value/Sh7.383 USD
Cash/Share6.541 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)29.10 USD
Upside (mean)+83.8%
Target Range18.00 USD – 37.00 USD
$18.00+83.8% to mean$37.00
# Analysts10
Ownership
Shares Out.55.24M
Float42.42M
Insiders2.97%
Institutions105.95%
Short Interest
Short Ratio15.0d
Short % Float26.62%
Short % Out.23.03%
Shares Short12.04M
Short (prev mo.)13.31M
Technical
SMA 5011.37 (+39.2%)
SMA 2009.866 (+60.4%)
Beta2.69
S&P 52W Chg18.16%
Avg Vol (30d)744.80K
Avg Vol (10d)1.30M
Technical Indicators
RSI (14)74.2
MACD1.0360
MACD Signal0.4009
MACD Hist.+0.6351
BB Upper15.43 USD
BB Middle11.40 USD
BB Lower7.361 USD
BB Width70.82%
ATR (14)1.016 USD
Vol Ratio (20d)1.20x